Treace Medical Concepts (TMCI) Common Equity (2020 - 2026)

Treace Medical Concepts has reported Common Equity for 7 years, with the latest figure at $77.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 26.72% year-over-year to $77.2 million; the trailing twelve-month figure through Mar 2026 stood at $77.2 million (down 26.72% YoY), and the FY2025 full-year result was $87.3 million, down 22.64% from the prior year.
• Common Equity for Q1 2026 stood at $77.2 million, down from $87.3 million in the prior quarter.
• The five-year high for Common Equity was $157.6 million in Q1 2023, with the low at $60.5 million in Q4 2022.
• Historically, Common Equity has averaged $104.6 million across 5 years, with a median of $104.9 million in 2024.
• The largest YoY upside for Common Equity was 12792.69% in 2022 against a maximum downside of 36.12% in 2022.
• Treace Medical Concepts' Common Equity stood at $60.5 million in 2022, then surged by 127.89% to $137.9 million in 2023, then fell by 18.16% to $112.9 million in 2024, then slipped by 22.64% to $87.3 million in 2025, then declined by 11.61% to $77.2 million in 2026.
• The last three Common Equity figures came in at $77.2 million (Q1 2026), $87.3 million (Q4 2025), and $89.2 million (Q3 2025), per Business Quant data.